Paper - WANFANG MED ONLINE

You Position: Home > Paper

ERCC1, BRCA1, RRM1 in NSCLC

( views:312, downloads:65 )

Author:: No author available

Journal Title:: CANCER RESEARCH AND CLINIC

Issue:: 7

DOI:: 10.3760/cma.j.issn.1006-9801.2007.07.002

Key Word:: ERCC1;BRCA1;RRM1;癌,非小细胞肺;DNA修复

Abstract：阐述了近年来非小细胞肺癌(NSCLC)化疗敏感性与DNA切除修复交叉互补基因1(ERCC1)、乳腺癌易感基因(BRCA1)、核苷酸还原酶1(RRM1)基因表达关系的研究进展,分析3个基因对NSCLC个体化化疗潜在的指导意义.

Reference

[1]李体远,Jing Jie yu,Eddie Reed.封闭ERCC1基因表达对卵巢癌细胞耐药的影响[J].2004,(2).
[2]Roig B,Barnadas A,Rosell R,etc.Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer.[J].2003,10(4).
[3]Rafael, Rosell,Kathleen D, Danenberg,Vincente, Alberola,etc.Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.[J].2004,10(4).
[4]Ceppi P,Danenberg KD,Novello S,etc.ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.[J].2006,17(12).
[5]B Douglas, Smith,Judith E, Karp.Ribonucleotide reductase: an old target with new potential.[J].2003,27(12).
[6]Holt JT,Abbott DW,Robinson Benion-C,etc.BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair.[J].1999,274(26).
[7]M, Dabholkar,J, Vionnet,F, Bostick-Bruton,etc.Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.[J].1994,94(2).
[8]Sanchez JJ,Alberola V,Camps C,etc.Targeted therapy in combination with gemcitabine in non-small cell lung cancer.[J].2003,30(4 Suppl.10).
[9]Taron M,Rosell R,Felip E,etc.BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.[J].2004,13(20).
[10]Hartman AR,Ford JM.BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair.[J].2002,32(1).
[11]C, Dumontet,K, Fabianowska-Majewska,D, Mantincic,etc.Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562.[J].1999,106(1).
[12]Takahisa, Furuta,Takahiro, Ueda,Gregory, Aune,etc.Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells.[J].2002,62(17).
[13]A, Husain,G, He,E S, Venkatraman,etc.BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).[J].1998,58.
[14]Jennifer E, Quinn,Richard D, Kennedy,Paul B, Mullan,etc.BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.[J].2003,63(19).
[15]Sanchez JM,Taron M,Rosell R,etc.Applications of genomics in NSCLC.[J].2005,50(Suppl.2).
[16]Li ZR,Gautam A,Bepler G.RRM1-induced metastasis suppression through PTEN-regulated pathways.[J].2003,22(14).
[17]Y G, Goan,B, Zhou,E, Hu,etc.Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line.[J].1999,59(17).
[18]Hamilton TC,Ferry KV,Johnson SW.Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.[J].2000,60(9).
[19]Sharma S,Cantor A,Robinson L,etc.RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer.[J].2004,22(10).
[20]Bostick Bruton-F,Slavsky D,Reed E,etc.Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.[J].2000,20(2A).
[21]M, Monzo,R, Rosell,M, Taron.Drug resistance in non-small cell lung cancer.[J].2001,34 Suppl 2.